1-氮杂双环[2.2.1]庚烷-4-甲腈 | 133366-28-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-氮杂双环[2.2.1]庚烷-4-甲腈
• 英文名称: 4-cyano-1-azabicyclo<2.2.1>heptane
• 英文别名: 1-Azabicyclo[2.2.1]hept-4-yl carbonitrile；1-Azabicyclo[2.2.1]heptane-4-carbonitrile
• CAS: 133366-28-6
• 化学式: C₇H₁₀N₂
• mdl: MFCD18806519
• 分子量: 122.17
• InChiKey: KRWYBTQGXVMLBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-氮杂双环[2.2.1]庚烷-4-甲腈 在 甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 26.5h， 生成 4-(2-methyltetrazol-5-yl)-1-azabicyclo[2.2.1]heptane
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007
• 作为产物：
  描述：

  1-azabicyclo[2.2.1]heptane-4-carbonyl chloride hydrochloride 在 吡啶 、 氨 、 三氟乙酸酐 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.25h， 生成 1-氮杂双环[2.2.1]庚烷-4-甲腈
  参考文献：
  名称：

  Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands

  摘要：

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.

  DOI：

  10.1021/jm00091a007

文献信息

• 5-HT 3 RECEPTOR AGONIST, NOVEL THIAZOLE DERIVATIVE, AND INTERMEDIATE THEREFOR
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0749966A1

  公开（公告）日：1996-12-27

  A 5-HT3 receptor agonist containing a thiazole derivative represented by general formula (I) as the effective ingredient; a specified compound useful as a 5-HT3 receptor agonist; and a specified thioamide derivative useful as an intermediate therefor. wherein each symbol represents the following meaning: Ring A: the following ring which may be substituted by one or more substituents selected from the group consisting of a halogen atom, a lower alkyl group and a lower alkoxyl group: 1) a benzene ring, or 2) a 5-membered or 6-membered unsaturated heterocyclic ring having one or two hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, L1 and L2: one of them represents a single bond, and the other one represents non-existence, or an alkylene group having 1 to 4 carbon atoms or an alkenylene group having 2 to 5 carbon atoms, R: a group represented by one of the following formulae: L3: a lower alkylene group, L4: a single bond or a lower alkylene group, R1 and R2: the same or different and individually a hydrogen atom, a lower alkyl group or an amino-protecting group, R3: a hydrogen atom, a lower alkyl group, an oxo group or a protected or unprotected amino group, R4: non-existence or a hydrogen atom, a lower alkyl group, an aralkyl group or an amino-protecting group, Ring B: the following monocyclic or bicyclic ring which may contain an oxygen atom: 1) a nitrogen-containing saturated heterocyclic ring having 4 to 16 ring-forming atoms, or 2) a nitrogen-containing heterocyclic ring having one unsaturated bond and 4 to 16 ring-forming atoms, and Ring D: a saturated carbon ring having 4 to 8 ring-forming atoms,

  一种 5-HT3 受体激动剂，含有作为有效成分的通式(I)代表的噻唑衍生物；一种用作 5-HT3 受体激动剂的特定化合物；以及一种用作其中间体的特定硫酰胺衍生物。 其中各符号代表以下含义： 环 A：可被选自卤素原子、低级烷基和低级烷氧基的一个或多个取代基取代的下环： 1) 苯环，或 2) 5 元或 6 元不饱和杂环，其中有一个或两个杂原子，选自由氮原子、氧原子和硫原子组成的组、 L1 和 L2：其中一个代表单键，另一个代表不存在的键，或代表具有 1 至 4 个碳原子的亚烷基或具有 2 至 5 个碳原子的烯基、 R：由下式之一代表的基团： L3：低级亚烷基、 L4：单键或低级亚烷基、 R1和R2：相同或不同，各自为氢原子、低级烷基或氨基保护基团、 R3：一个氢原子、一个低级烷基、一个氧代基团或一个受保护或不受保护的氨基、 R4：不存在或为氢原子、低级烷基、芳烷基或氨基保护基团、 环 B：可含有一个氧原子的单环或双环： 1) 具有 4 至 16 个成环原子的含氮饱和杂环，或 2) 具有一个不饱和键和 4 至 16 个成环原子的含氮杂环，以及 环 D：具有 4 至 8 个成环原子的饱和碳环、
• Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands
  作者：Sarah M. Jenkins、Harry J. Wadsworth、Steven Bromidge、Barry S. Orlek、Paul A. Wyman、Graham J. Riley、Julie Hawkins

  DOI：10.1021/jm00091a007

  日期：1992.6

  The effect of variation of the 1-azabicyclic substituent on the novel 1,2,3-triazol-4-yl-, 1,2,4-triazol-1-yl-, tetrazol-5-yl-, and tetrazol-2-yl-based muscarinic receptor ligands ha, been studied, and the exo-azabicyclic[2.2.1]hept-3-yl substituent was found to give the most potent and efficacious compounds. In addition, variation of the second substituent on 1,2,4-triazol-1-yl- and tetrazol-2-yl-based muscarinic receptor ligands has yielded a series of novel compounds with high potencies and efficacies, ranging from full agonists to antagonists. Small lipophilic electron withdrawing substituents give potent but low efficacy compounds, while small polar electron donating substituents give potent and efficacious compounds. The activity of these compounds is described in terms of a model of the receptor involving lipophilic and hydrogen bonding interactions. These compounds provide muscarinic ligands with high potency and a range of efficacies suitable for testing as candidate drugs in the treatment of Alzheimer's disease.